Bill Gates Commits $10 Million More for Alzheimer’s Research to ‘Part the Cloud’

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top healthcare news. To get it delivered daily to your in-box, sign up here. Hello and happy Monday, readers! I hope you enjoyed your weekend. Bill Gates is continuing to pour money into Alzheimer’s research efforts. The billionaire philanthropist is funding
Complete Reading

Good afternoon, readers (and a Happy Halloween to those who “celebrate.”) China is in the early throes of a biotech explosion. And American companies have taken notice. On Thursday, U.S. biotech giant Amgen announced that it will take a 20.5% stake in BeiGene, a firm which IPO’d in the U.S. back in 2016 with a
Complete Reading

Hello and happy hump day, readers. Quest Diagnostics is out with a new report that underscores how far we have to go when it comes to the doctor-patient relationship and mitigating prescription drug addiction. The study, a poll of 500 primary care doctors and millions of data points from prescription drug monitoring labs, has some
Complete Reading

Good afternoon, readers. October 10 is World Mental Health Day—and Fortune has a special guest piece by Arianna Huffington (media titan, CEO of the wellness group Thrive Global, and one of our Brainstorm Health conference co-chairs) on the importance of shifting the theoretical conversations surrounding mental health to actual, well, action. How, exactly, can we
Complete Reading

Hello and happy Monday, readers. Fortune sat down with Brad Loncar, a biotech investor who specializes in cancer immunotherapy, at our offices last week. Loncar runs both a U.S.-based index fund for cancer drug companies and, more recently, launched another one focused on China. It was a fascinating conversation that covered everything from the U.S.
Complete Reading

Good evening, readers. The Trump administration made a pretty significant move today on health care policy—President Trump issued an executive order on Medicare aiming to further privatize the public program, which covers some 60 million elderly and disabled Americans. To be clear, Medicare already contains a significant private component. More than 20 million beneficiaries (or
Complete Reading

Hello and happy hump day, readers. Perhaps it was inevitable in the face of lawsuits, regulatory crackdowns, reports of horrifying lung illnesses, and a general sense of unease—but Kevin Burns, CEO of the privately-held firm Juul, is stepping down from his perch. The Juul CEO’s sudden departure is just one chapter in this rapidly unfolding
Complete Reading

Good afternoon, readers. Responding to widespread outrage, in the midst of an election season, lawmakers are proposing a whole bunch of initiatives to crack down on high prescription drug prices in America. The latest additions to the debate (none of which are necessarily expected to pass) include an earlier plan from Republican Sen. Chuck Grassley
Complete Reading

Happy Friday, readers. In 2018, Moderna Therapeutics filed for a titanic IPO (at that point, the largest biotech public offering in history). It raised $604 million, setting the company up for an initial valuation of about $7.5 billion. But, as is the story with so many pre-market biotechs, controversy was just around the corner. Moderna’s
Complete Reading

Hello and happy hump day, readers! The reckoning has begun for the e-cigarette and vaping industry. Following increasingly urgent reports of an epidemic of youth vaping and hundreds of cases of mysterious lung illnesses—and, now, six deaths—allegedly linked to such products, the Trump administration is moving to ban flavored e-cigarettes from the market altogether. “The
Complete Reading

Create Account



Log In Your Account